Capital Research Global Investors
PBYI icon

Capital Research Global Investors’s Puma Biotechnology PBYI Stock Holding History

Capital Research Global Investors’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-676,600
Closed -$20.2M – 420
2016
Q2 		$20.2M Hold
676,600
– – 0.01% 363
2016
Q1 		$19.9M Sell
676,600
-1,150,000
-63% -$52M 0.01% 377
2015
Q4 		$143M Buy
1,826,600
+65,760
+4% +$5.16M 0.05% 255
2015
Q3 		$133M Sell
1,760,840
-871,472
-33% -$82.4M 0.05% 265
2015
Q2 		$307M Buy
2,632,312
+591,572
+29% +$107M 0.1% 201
2015
Q1 		$482M Buy
2,040,740
+96,000
+5% +$20.5M 0.16% 135
2014
Q4 		$368M Buy
1,944,740
+109,240
+6% +$24.2M 0.13% 179
2014
Q3 		$438M Buy
+1,835,500
New +$377M 0.15% 151

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Capital Research Global Investors's PBYI Position: Q3 2016 in Review

Capital Research Global Investors sold out of Puma Biotechnology (PBYI) in Q3 2016, closing a stake of 676,600 shares — an estimated $20.2M sold.

Capital Research Global Investors first reported a position in PBYI in Q3 2014 and held it in 8 quarters. The position peaked at $482M in Q1 2015. 149 funds tracked by Wall St. Rank hold PBYI as of Q3 2016.

  • Capital Research Global Investors reported no remaining Puma Biotechnology position as of Q3 2016 after selling out during the quarter.
  • Capital Research Global Investors sold 676,600 Puma Biotechnology shares in Q3 2016, an estimated $20.2M.
  • Capital Research Global Investors first reported a position in Puma Biotechnology in Q3 2014 and held it in 8 quarters.
  • Capital Research Global Investors's Puma Biotechnology position peaked at $482M in Q1 2015.
  • 149 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2016.

Based on Capital Research Global Investors's 13F filing for Q3 2016, filed 14 Nov 2016.